Thaum Lub Xya Hli 27, 2023, Lilly tshaj tawm tias Mount-3 txoj kev tshawb fawb ntawm Tirzepatide rau kev kho cov neeg mob rog rog thiab kev tshawb nrhiav Mount-4 rau kev tswj kev poob phaus ntawm cov neeg mob rog tau mus txog qhov kawg taw tes thiab qhov tseem ceeb thib ob qhov kawg.Qhov no yog qhov kev vam meej thib peb thiab thib plaub theem III kev tshawb fawb tau los ntawm Tirzepatide tom qab Mount-1 thiab Mount-2.
SURMOUNT-3 (NCT04657016) yog multicenter, randomized, ob-dig muag, sib npaug, cov tshuaj placebo-tswj kev sim nkag rau tag nrho ntawm 806 tus neeg koom tsim los ua kom pom Tirzepatide qhov zoo tshaj ntawm cov placebo raws li qhov feem pua ntawm cov kev hloov pauv hauv qhov hnyav tom qab randomization thiab feem pua. Cov neeg koom nrog poob ≥5% tom qab randomization ntawm 72 lub lis piam.
Qhov kev tshawb fawb SURMOUNT-3 tau pom tias Tirzepatide tau ntsib txhua qhov kawg, uas yog tias tom qab 72 lub lis piam ntawm kev kho mob, cov neeg mob hauv pab pawg Tirzepatide tau ua tiav qhov feem pua ntawm qhov hnyav dua los ntawm qhov pib piv rau cov placebo, thiab feem pua ntawm cov neeg mob ntau dua hauv pawg Tirzepatide. ua tiav qhov feem pua yuav poob ntau dua 5%.Cov ntaub ntawv kho mob tshwj xeeb tau pom tias cov neeg mob kho nrog Tirzepatide poob qhov nruab nrab ntawm 21.1% ntawm lub cev hnyav piv rau cov placebo;Ua ke nrog 12-lub lim tiam kev cuam tshuam, cov neeg mob kho nrog Tirzepatide poob qhov nruab nrab ntawm 26.6 feem pua ntawm lawv lub cev qhov hnyav.Tsis tas li ntawd, 94.4% ntawm cov neeg mob poob ≥5% ntawm lawv qhov hnyav hauv pawg Tirzepatide, piv nrog 10.7% hauv pawg placebo.
SURMOUNT-4 (NCT04660643) yog multicenter, randomized, ob qhov muag tsis pom kev, sib npaug, cov tshuaj placebo tswj kev sim nkag rau tag nrho 783 tus neeg koom tsim los ua kom pom tias Tirzepatide zoo dua rau cov placebo hauv feem pua qhov hnyav ntawm 88-lub lim tiam randomization.
Cov txiaj ntsig tau pom tias tom qab ob lub qhov muag tsis pom kev ntawm 37 ~ 88 lub lis piam, cov neeg mob hauv pawg Tirzepatide poob hnyav dua li cov placebo.Hais txog kev nyab xeeb, tsis yog SURMOUNT-3 lossis SURMOUNT-4 cov kev tshawb fawb tau pom cov cim kev nyab xeeb tshiab.
Txij li thaum pib ntawm Novo Nordisk's blockbuster noj tshuaj Semaglutide, ua ke nrog Musk qhov kev pom zoo muaj zog, nws tau dhau los ua cov khoom lag luam nrov hauv Is Taws Nem thiab cov huab tais poob tam sim no.Kev poob phaus kev lag luam xav tau loj, thiab tsuas muaj ob GLP-1 cov tshuaj poob phaus tam sim no nyob rau hauv kev ua lag luam, Liraglutide thiab Semaglutide, tab sis Liraglutide yog ib qho kev npaj luv luv, uas tsis tuaj yeem sib tw nrog kev npaj ua haujlwm ntev raws li tus neeg mob ua raws. , thiab tam sim no lub ntiaj teb poob phaus ib ntus belongs rau Semaglutide.
Tsis tas li ntawd tus huab tais ntawm GLP-1 teb, Lilly xav tau dej hiav txwv xiav ntawm kev ua lag luam poob phaus - yog li Lilly tau pib muaj kev sib tw thiab thawj thawj koom ruam ntawm Tirzepatide mus txeeb ib qho chaw hauv khw poob.
Tirzepatide yog ib lub limtiam GIPR / GLP-1R dual agonist, GIP (glucose-dependent insulin stimulating polypeptide) yog lwm tus tswvcuab ntawm glucagon peptide tsev neeg, nrog rau kev txhawb nqa cov tshuaj insulin secretion hauv insulin-dependent yam thiab stimulating glucagon secretion hauv hypoglycemic. xeev, GIPR / GLP-1R dual agonist tuaj yeem tsim kev tswj ntshav qab zib, poob phaus thiab lwm yam teebmeem los ntawm kev txhawb nqa ob qho tib si GIP thiab GLP-1 txoj hauv kev qis.Tirzepatide tau pom zoo los ntawm FDA hauv 2022-5 (lub npe lag luam: Mounjaro) rau kev siv ua ke nrog kev noj haus thiab kev tawm dag zog los txhim kho glycemic tswj hauv cov neeg laus uas muaj ntshav qab zib hom 2.
Post lub sij hawm: Sep-18-2023